SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

Therapy optimization: Endocrine approaches in…

AI based prognostic test

Giredestrant will replace current adjuvant therapy

SERDs now in adjuvant therapy

PALLAS trial and ctDNA

SERDs in early breast cancer - the new era has begun?

Surgery remains soc in low risk EBC

Revolution in adjuvant endocrine therapy?

ctDNA analysis could optimize the approach in HER2+

Optimized endocrine therapy for premenopausal patients

Quality of live data DB11

Significant innovations in early and metastatic HER2+…

sTILs with deep learning AI

Olaparib neoadjuvant with high PCR rates

Carboplatin in adjuvant setting of TNBC

In addition to pCR, ctDNA is prognostically relevant…

Otimização da terapia: abordagens endócrinas em…

SERDy we wczesnym raku piersi -początek nowej epoki?

Carboplatino nel contesto adiuvante del TNBC

El análisis del ADN libre circulante podría optimizar…

La chirurgia rimane lo standard di cura nei casi di…

ASCENT-07 a negative trial

Palbociclib likely delays CNS progression

Traditional chemotherapy should not be forgotten as…

Elacestrant is a good combination partner for HR+ HER2+…

Elacestrant as oral endocrine backbone

Updated results of VIKTORIA-1

No improvement over standard therapy

The significance of SG is more clearly defined

Biomarker and clinical subgroup analysis of evERA…

Chemotherapy-free treatment: a promising therapeutic…

Triple-positive MBC: less chemotherapy, more endocrine…

Make a hot tumor out of a cold tumor

Significant innovations in early and metastatic HER2+…

New evidence for oral SERDs

ctDNA Dynamics as a biomarker of response

Monitoring of ILD

Maintenance therapy HER2+ Tucatinib as a new option

Tucatinib a new SERD in the adjuvant setting

Jeszcze nie czas na rezygnację z tradycyjnej…

Nuove prove a favore dei SERD orali

Résultats actualisés de VIKTORIA-1

Sem melhorias em relação à terapia padrão

Tucatinib, un nouveau SERD dans le cadre d'un…

La dinamica del ctDNA come biomarcatore di risposta

Risultati aggiornati di VIKTORIA-1